Travis Wold

CEO, Imagenomix Corp

Travis Wold is the CEO of Imagenomix Corp., an NYU spinout advancing cancer diagnostics with artificial intelligence. He leads the company’s mission to detect cancer-causing mutations directly from H&E pathology slides, creating faster and more accurate insights for physicians, patients, and pharmaceutical partners.

Under his leadership, Imagenomix secured its first pharmaceutical client and is developing a pipeline of novel, patented products scheduled for launch in 2026 and 2027. These innovations are designed to transform precision oncology and real-time diagnostics across both clinical and pharmaceutical settings.

With a strong background in medical technology ventures, Travis is known for building teams that unite world-class pathologists, oncologists, and AI experts. He continues to guide Imagenomix toward reshaping the future of cancer care by combining breakthrough science with practical clinical impact.